M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Price:
15.63
USD
-2.68%
Market Closed
Market Cap:
$1.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
US |
|
S
|
Sunline AG
XBER:SU3
|
DE |
|
L
|
Linde PLC
XETRA:LIN
|
UK |
|
Victoria's Secret & Co
NYSE:VSCO
|
US |
|
G
|
GigaCloud Technology Inc
NASDAQ:GCT
|
HK |
|
W
|
Wins Finance Holdings Inc
OTC:WINSF
|
US |
|
Bintang Oto Global Tbk PT
IDX:BOGA
|
ID |
|
B
|
Bannix Acquisition Corp
NASDAQ:BNIX
|
US |
|
Ariake Japan Co Ltd
TSE:2815
|
JP |
|
Japan Exchange Group Inc
TSE:8697
|
JP |
|
Fresnillo PLC
LSE:FRES
|
MX |
|
Marui Group Co Ltd
TSE:8252
|
JP |
|
S
|
SDS Group Bhd
KLSE:SDS
|
MY |
|
Squirrel Media SA
MAD:SQRL
|
ES |
|
S
|
SPS Finquest Ltd
BSE:538402
|
IN |
|
Atenor SA
XBRU:ATEB
|
BE |
|
D
|
Deere & Co
XBER:DCO
|
US |
|
A
|
Advance Metering Technology Ltd
BSE:534612
|
IN |
|
S
|
Seronics Co Ltd
KOSDAQ:042600
|
KR |
|
T
|
Trecora Resources
F:A34
|
US |
|
O
|
Origin Property PCL
SET:ORI
|
TH |
|
Lexagene Holdings Inc
XTSX:LXG
|
US |
|
F
|
FL Entertainment NV
AEX:FLE
|
FR |
|
Stewart Information Services Corp
NYSE:STC
|
US |
Relative Value
The Relative Value of one GLUE stock under the Base Case scenario is hidden USD. Compared to the current market price of 15.63 USD, Monte Rosa Therapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GLUE Relative Value
HIDDEN
Multiples Across Competitors
GLUE Competitors Multiples
Monte Rosa Therapeutics Inc Competitors
Monte Rosa Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
1.1B USD | 6.3 | 54.4 | 44.4 | 87.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
